Nuwellis Valuation

Is 22S undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 22S when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 22S's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 22S's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 22S?

Key metric: As 22S is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 22S. This is calculated by dividing 22S's market cap by their current revenue.
What is 22S's PS Ratio?
PS Ratio	0.3x
Sales	US$9.01m
Market Cap	US$2.42m

22S key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.2x
Enterprise Value/EBITDA	-0.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 22S's PS Ratio compare to its peers?

The above table shows the PS ratio for 22S vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	4.3x
MF6 MagForce	3.3x	50.9%	€3.6m
AUG Audientes	12.6x	n/a	€6.9m
MF6 MagForce	0.3x	n/a	€366.9k
GME Geratherm Medical	0.8x	1.9%	€15.0m
22S Nuwellis	0.3x	36.3%	€2.4m

Price-To-Sales vs Peers: 22S is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (1.1x).

Price to Sales Ratio vs Industry

How does 22S's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

5 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	3.5x	6.0%
22S Nuwellis	0.3x	36.3%	US$2.42m
DRW3 Drägerwerk KGaA	0.2x	4.2%	US$827.50m
PHH2 Paul Hartmann	0.3x	n/a	US$791.49m

5 Companies		Estimated Growth	Market Cap
Industry Avg.	3.5x	14.2%
22S Nuwellis	0.3x	61.9%	US$2.42m

No more companies

Price-To-Sales vs Industry: 22S is good value based on its Price-To-Sales Ratio (0.3x) compared to the European Medical Equipment industry average (3.8x).

Price to Sales Ratio vs Fair Ratio

What is 22S's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

22S PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.3x
Fair PS Ratio	1.4x

Price-To-Sales vs Fair Ratio: 22S is good value based on its Price-To-Sales Ratio (0.3x) compared to the estimated Fair Price-To-Sales Ratio (1.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Shandong Weigao Group Medical Polymer

HK$20.1b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

-1.0%

-38.8%

LNA Santé

€244.4m

Engages in the management and operation of health establishments.

2N3

€23.25

-6.1%

16.0%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

0.5%

-82.5%